Document is current
Any future updates will be listed below
-
Authors
Torrent, Anna https://orcid.org/0000-0002-3727-5716
Morgades, Mireia
Iacoboni, Gloria
Reguera, Juan Luis https://orcid.org/0009-0009-6408-1747
Kwon, Mi https://orcid.org/0000-0002-3855-7774
López Corral, Lucia
Hernani, Rafael https://orcid.org/0000-0003-1043-8076
Ortiz-Maldonado, Valentín https://orcid.org/0000-0003-4699-6862
Sanz, Jaime https://orcid.org/0000-0001-6934-4619
Caballero Gonzalez, Ana Carolina https://orcid.org/0000-0002-4950-5259
Guerra, Luisa
Sánchez Pina, José María
Mussetti, Alberto https://orcid.org/0000-0002-4088-036X
Garcia-Sancho, Alejandro Martin
Bastos-Oreiro, Mariana https://orcid.org/0000-0002-9431-4646
Delgado, Javier
Carpio, Cecilia
Sancho, Juan-Manuel https://orcid.org/0000-0001-7168-6538
Pérez-Martinez, Antonio
Barba, Pere
- License Information
-
More Information
Article History
Received: 30 May 2025
Revised: 4 August 2025
Accepted: 15 September 2025
First Online: 30 September 2025
Competing interests
: - Anna Torrent: Advisory Board fees from Amgen, Incyte. Honoraria from Kite/Gilead, Incyte, Pfizer, Amgen, Servier, and SERB. Gloria Iacoboni: Consultancy and Honoraria from Novartis, Roche, Kite/Gilead, Bristol-Myers Squibb, Abbvie, Janssen, Sandoz, Miltenyi, and AstraZeneca. Alejandro Martin García-Sancho: Honoraria and/or consulting fees: Abbvie, AstraZeneca, BeiGene, BMS, Genmab, Gilead/Kite, GSK, Ideogen, Incyte, Janssen, Kyowa Kirin, Lilly, Miltenyi, Regeneron, Roche, Sobi, Takeda. Research support: Gilead/Kite. Cecilia Carpio: Consultancy/Advisory from Regeneron, BMS, Takeda. Honoraria from Takeda, Janssen, and Novartis. Consultancy from Novotech. Pere Barba: Advisory Board and consultancy from Allogene, Amgen, Autolus, BMS/Celgene, Kite/Gilead, Incyte, Miltenyi Biomedicine, Novartis, Nektar, Pfizer and Pierre Fabre. For the remaining authors, no relevant conflicts of interest were declared.
